证券之星消息，截至2025年7月16日收盘，茂化实华(000637)报收于4.17元，上涨0.48%，换手率 2.81%，成交量10.34万手，成交额4313.78万元。 7月16日的资金流向数据方面，主力资金净流出470.59万元，占总成交额10.91%，游资资金净流出 484.77万元，占总成交额11.24%，散户资金净流入955.37万元，占总成交额22.15%。 近5日资金流向一览见下表： 近5日融资融券数据一览见下表： 该股主要指标及行业内排名如下： | 指标 | 茂化实华 | 石油行业均值 | 行业排名 | | --- | --- | --- | --- | | 总市值 | 21.68亿元 | 1869.95亿元 | 20 20 | | 净资产 | 7.23亿元 | 1831.71亿元 | 17 20 | | 净利润 | -3506.79万元 | 48.89亿元 | 17 20 | | 市盈率(动) | -15.45 | 26.07 | - 20 | | 市净率 | 3.54 | 2.82 | 17 20 | | 毛利率 | 3.6% | 20.82% | 19 20 | | 净利率 | -4.9 ...

二、主要原材料的采购量、消耗量及价格变动情况 山西焦化股份有限公司 2025年第二季度主要经营数据公告 重要提示：本公司及董事会全体成员保证公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别 及连带责任。 根据《上海证券交易所上市公司自律监管指引第3号——行业信息披露第 十三号—化工》有关规定和披露要求，公司2025年第二季度主要经营数据如 下： | 主要产品 | 经营指标 | 单位 | 2025 年第二季度 | 2025年第一季度 | 变动比率（%） | | --- | --- | --- | --- | --- | --- | | 焦炭 | 产量 | 吨 | 735,647.30 | 731,962.69 | 0.50 | | | 销量 | 吨 | 761,790.27 | 727,501.76 | 4.71 | | | 销售收入 （不含税） | 元 | 981,617,628.62 | 1,055,586,825.97 | -7.01 | | | 平均售价 （不含税） | 元/吨 | 1,288.57 | 1,450.97 | -11.19 | | 沥青 | ...

在徐晰人逐渐增强其对北大医药掌控力的同时，这家公司身上 的"隐疾"开始爆发。 作者：黄一帆 封图：图虫创意 入主8个月后，北大医药（000788.SZ）新实控人徐晰人已基本完成了对管理层的洗牌。 7月5日，北大医药发布多条人事变动公告。该公司宣布，经董事会决议，聘任实控人、董事长徐 晰人为总裁，余孟川为常务副总裁。 自去年12月，徐晰人代替"平安系"成为上市公司新任实控人后，北大医药管理层开始频繁变动。 在徐晰人逐渐增强其对北大医药掌控力的同时，这家公司身上的"隐疾"开始爆发。 就在上述董事会召开前几日，北大医药发布公告称，因相关历史遗留问题，该上市公司经营办公场 所受到近百个离退休人员的冲击和围堵，严重干扰了公司行政办公秩序，造成了一定影响。所谓 的"历史遗留问题"特指住房和离退休福利待遇等问题。 除面临管理问题外，业绩稳定性也成为横在新管理层面前的一道难题。此前，北大医药与同为方正 集团旗下的北京大学国际医院（以下简称"北大国际医院"）关联交易频繁。2024年，北大国际医 院是北大医药的第一大客户。 而在北大医药易主后，来自老股东的支持也将随之消失。7月11日，记者致电北大医药证券部，该 公司证券部人士表 ...

入主8个月后，北大医药（000788）（000788.SZ）新实控人徐晰人已基本完成了对管理层的洗牌。 7月5日，北大医药发布多条人事变动公告。该公司宣布，经董事会决议，聘任实控人、董事长徐晰人为 总裁，余孟川为常务副总裁。 自去年12月，徐晰人代替"平安系"成为上市公司新任实控人后，北大医药管理层开始频繁变动。 在徐晰人逐渐增强其对北大医药掌控力的同时，这家公司身上的"隐疾"开始爆发。 就在上述董事会召开前几日，北大医药发布公告称，因相关历史遗留问题，该上市公司经营办公场所受 到近百个离退休人员的冲击和围堵，严重干扰了公司行政办公秩序，造成了一定影响。所谓的"历史遗 留问题"特指住房和离退休福利待遇等问题。 除面临管理问题外，业绩稳定性也成为横在新管理层面前的一道难题。此前，北大医药与同为方正集团 旗下的北京大学国际医院（以下简称"北大国际医院"）关联交易频繁。2024年，北大国际医院是北大医 药的第一大客户。 这意味着，徐晰人仅用了3000多万元便拿下了一家总市值近40亿元的上市公司控制权。而在此前，2022 年平安系通过平安人寿出资482亿元参与方正集团的破产重整，才间接取得北大医药的控制权。 这一极具 ...

2025 年皮肤病药物品牌推荐 创新药物探秘，精准匹配患者需求 | 一、市场背景 | | 2 | | --- | --- | --- | | 1.1 摘要 | | 2 | | 1.2 皮肤病药物定义 | | 2 | | 1.3 市场演变 | | 2 | | 二、市场现状 | | 3 | | 2.1 市场规模 | | 3 | | 2.2 市场供需 | | 3 | | 三、市场竞争 | | 4 | | 3.1 市场评估维度 | | 4 | | 3.2 市场竞争格局 | | 5 | | 3.3 十大品牌推荐 | | 5 | | 四、发展趋势 | | 7 | | 4.1 技术革新将成为核心驱动力 | | 7 | | 4.2 竞争格局方面，本土企业将凭借渠道优势和创新升级巩固主导地位 | | 7 | | 4.3 政策与资本共振将加速产业升级 | | 7 | 2025 年皮肤病药物品牌推荐 一、市场背景 1.1 摘要 皮肤病药物行业专注于治疗皮肤疾病，产品多样，市场需求强劲。行业受高监管壁垒 和政策影响大，但患者需求增长驱动市场扩容。预计未来市场规模将持续增长，新型 外用治疗方式的获批将推动行业进一步发展，如科笛集团等企 ...

Core Viewpoint - The transformation of traditional Chinese pharmaceutical companies towards innovation is gaining momentum, exemplified by Dongyang Sunshine Pharmaceutical's IPO application and its focus on innovative drug development [1][2]. Group 1: Innovation Transformation - Dongyang Sunshine Pharmaceutical has accumulated over 20 years of research and development experience, owning 150 approved drugs across China, the US, and Europe, which provides a solid foundation for its innovative R&D [2]. - The company plans to invest 7.92 billion RMB, 8.27 billion RMB, and 8.88 billion RMB in R&D from 2022 to 2024, representing 20.8%, 13.0%, and 22.1% of total revenue respectively, indicating a commitment to high R&D spending [2]. - Dongyang Sunshine has a complete production line from raw materials to formulations, with leading facilities for solid formulations and biopharmaceuticals, and has received multiple GMP certifications in China, the US, and Europe [2]. Group 2: Sales and Distribution - The company has a large sales and distribution network with nearly 2,000 sales professionals, covering 32 provincial administrative regions and over 25,000 hospitals in China [3]. - Dongyang Sunshine is positioned to be one of the first Chinese pharmaceutical companies to obtain approval for insulin in the US, expanding its global market reach [3]. Group 3: Product Pipeline and Clinical Development - Dongyang Sunshine has successfully launched three innovative hepatitis C drugs and is expanding its pipeline to include a SGLT-2 oral diabetes drug and over ten new drugs in II and III phase clinical trials targeting various diseases [3][9]. - The company is focusing on oncology, with over 20 innovative pipelines, including the FLT3 inhibitor, Clifofitinib, which is currently in III phase clinical trials for acute myeloid leukemia (AML) [4][5]. Group 4: Market Potential - Clifofitinib has a global sales peak potential of 1 billion USD, with an expected annual sales peak of 3-4 billion RMB in China, highlighting its significant market opportunity [8]. - The company has established a commercial partnership for Clifofitinib with Shenyang Sanofi Pharmaceutical to enhance market penetration upon its launch [8]. Group 5: Future Outlook - Dongyang Sunshine is redefining its innovation boundaries, transitioning from a "flu expert" to a globally competitive innovative pharmaceutical company, with a focus on advanced technologies such as AI in drug development [11][12]. - The company aims to continue breakthroughs in metabolic diseases, anti-infection, and oncology, potentially becoming a benchmark for innovation transformation among local pharmaceutical companies [12].

Core Viewpoint - The company, Shanxi Yongdong Chemistry Industry Co., Ltd., is responding to an inquiry from the Shenzhen Stock Exchange regarding its application for a specific stock issuance, detailing its financial performance, inventory management, and market conditions affecting its operations [1]. Financial Performance - The company's operating revenue for the reporting periods was 375.90 million yuan, 450.40 million yuan, and showed fluctuations in profit margins with rates of 12.50%, 4.15%, 5.33%, and 4.99% [2]. - The company's inventory values at the end of each reporting period were 34.71 million yuan, 64.45 million yuan, with a significant portion of inventory being over one year old due to production halts [2]. - Fixed assets totaled 118.94 million yuan, with 35.85 million yuan being idle due to the suspension of a production project [2]. Market Conditions - The global carbon black market is projected to grow from 28.76 billion USD in 2024 to 41.28 billion USD by 2032, with a CAGR of 4.6% [10]. - China holds a significant position in the global carbon black industry, with a production capacity of 46.2% of the world's total as of 2023 [11]. - The carbon black industry in China is experiencing a gradual increase in production capacity and output, with a focus on improving product quality and technological advancements [12][13]. Product Pricing and Cost Analysis - The average procurement cost of coal tar, a primary raw material, has decreased significantly, aligning with market trends [6][19]. - The pricing model for carbon black products is based on raw material costs and market conditions, with quarterly or monthly adjustments made based on customer negotiations [7][8]. - The company’s carbon black product gross margin has shown stability, with fluctuations primarily driven by changes in raw material prices and market conditions [19][23]. Regulatory and Safety Issues - The company faced a fine of 500,000 yuan due to a suffocation incident, which raised concerns about compliance with safety regulations [3]. - The inquiry from the Shenzhen Stock Exchange also requested clarifications on the company's internal control measures regarding safety production [4]. Investment and Future Outlook - The company is expected to enhance its competitive edge through innovation and by expanding into high-performance carbon black markets, responding to increasing environmental regulations and market demands [15][16]. - The coal tar processing industry is shifting towards higher value-added products and improved resource utilization, indicating a potential growth area for the company [16].

Core Viewpoint - The article discusses the increase in patients presenting with "small blisters" on hands and feet during the summer, primarily caused by various skin conditions, with a focus on sweat eczema as the most common cause [1][2]. Group 1: Common Conditions - The most common condition leading to "small blisters" is sweat eczema, characterized by small blisters on the palms and soles, often accompanied by severe itching [2][3]. - Other potential causes include athlete's foot, hand-foot eczema, contact dermatitis, and hand-foot-mouth disease, each with distinct characteristics and treatment approaches [3][4]. Group 2: Symptoms and Diagnosis - Patients typically experience blisters on the sides of fingers, palms, and soles, with symptoms worsening at night or with heat, leading to potential secondary infections if scratched [2][3]. - Sweat eczema is noted for its self-limiting nature, often exacerbating in summer and improving in fall and winter, with recurrent episodes leading to skin thickening and cracking [2][3]. Group 3: Treatment Approaches - Treatment for sweat eczema focuses on symptomatic relief, with options like calamine lotion for itching and topical corticosteroids for severe cases [6]. - Athlete's foot requires maintaining dry skin and may involve antifungal medications, with an emphasis on completing the full treatment course to prevent recurrence [6]. - Hand-foot eczema treatment involves avoiding irritants and may include wet dressings during acute phases, transitioning to topical corticosteroids as the condition stabilizes [6]. - Contact dermatitis treatment emphasizes identifying and removing the irritant, followed by appropriate topical or oral medications as needed [6][7].

Group 1 - Kangyuan Pharmaceutical has launched a significant generic drug, Sumatriptan Naproxen Sodium Tablets, which fills a gap in the domestic market as the original manufacturer has not yet received approval for entry [2] - The sales of neurological system drugs in China remain substantial, maintaining a scale of over 100 billion yuan, with analgesics holding a market share exceeding 17% [2] - This new drug is the third product approved for Kangyuan Pharmaceutical this year, alongside other products in the neurological field, including Piracetam Injection and Pirfenidone Tablets [2] Group 2 - Kangyuan Pharmaceutical is advancing its "one body, two wings" strategy, focusing on both traditional Chinese medicine and expanding into chemical and biological drugs [2][3] - The company has made significant progress in chemical drug development, particularly in antiviral and anti-tumor areas, enhancing its product matrix [2] - In 2024, Kangyuan Pharmaceutical will complete the acquisition of 100% of Zhongxin Pharmaceutical, which specializes in the development of recombinant human cytokines and antibody biological drugs, further solidifying its growth strategy [3]

编辑丨王多鱼 排版丨水成文 电化学 在合成化学领域正经历复兴，并展现出极具吸引力的优势。通过合成化学策略重新利用天然酶在探索新的化学空间方面具有巨大潜力。包括定向进化、人 工酶和光酶催化在内的精妙策略已展现出其在学术界和工业界拓展酶应用的能力。 然而，电化学与酶的结合主要局限于复制先前已确立的酶的功能。利用电能实现酶的新反应性所面临的关键挑战包括兼容性问题以及异相电子转移的困难 。 如何 利用电化学驱动酶催化，去解锁非天然的新催化模式，仍有待突破。 该研究通过融合电催化和酶催化，成功解锁了 ThDP 依赖酶的新催化功能，实现醛到手性羧酸的动态动力学氧化新转化。该成果开辟了" 电驱动酶催化 "不对称合 成的新范式，为苯丙酸类药物的不对称生物合成提供了新途径。 在这项最新研究中，研究团队报道了通过二茂铁介导的电催化重塑焦磷酸硫胺素 （ThDP） 依赖性酶，从而解锁了α-支链醛的非天然动态动力学氧化。 这种稳健的电酶法能实现布洛芬、萘普生等十种( S )-芳基丙酸类抗炎药物的高效合成， 对映选择性高达 99%ee，适用于过表达该酶的所有细胞，并且酶负载量 低至 0.05 摩尔百分比。 2025 年 5 月 28 日 ...